Pneumococcal conjugated vaccines have been recommended in children for over a decade in many countries worldwide. Here we review the development of pneumococcal vaccines with a focus on the two types currently available for children and their safety record. We discuss also the effect of vaccines, including the 13-valent pneumococcal conjugate vaccine, on invasive pneumococcal diseases in children, particularly bacteraemia, pneumonia and meningitis, as well as on mucosal disease and carriage. In regions where immunization was implemented in young children, the number of invasive pneumococcal diseases decreased significantly, not only in the target age group, but also in younger and much older subjects. Challenges and future perspectives regarding the development of new 'universal' vaccines, which could bypass the current problem of serotype-specific protection in a context of serotype replacement, are also discussed.
Introduction
Diseases caused by Streptococcus pneumoniae (pneumococcus) constitute a major global public health problem. According to the WHO, about 14.5 million episodes of serious pneumococcal disease (uncertainty range 11.1-18.0 million) were estimated to have occurred in 2000, resulting in about 826 000 deaths (uncertainty range: 582 000-926 000) in children aged 1-59 months [1] .
Pneumococcus-related diseases are considered as the number one vaccine-preventable cause of death in children [2] . Pneumococcus causes mucosal diseases, such as acute otitis media, sinusitis, mastoiditis and other serious diseases, called invasive pneumococcal diseases (IPD), which include bacteraemia, meningitis, or pneumonia. The overall rate of IPD among children and adults is reported to be about 15/ 100 000 individuals per year [2] . Certain ethnic groups, such as African-Americans, Native Americans and Australian Aboriginals, are up to ten times more at risk for invasive disease, although it remains unclear whether this is the result of genetic components or environmental factors [3] [4] [5] . The main objective of pneumococcal vaccination in children is to decrease the incidence of IPD, but also to help prevent mucosal disease.
Almost all S. pneumoniae have an external polysaccharide capsule and more than 90 serotypes have been identified on the basis of antigenic differences in this capsule [6] [7] [8] . Streptococcus pneumoniae usually colonizes the nasopharynx and repeated sampling can yield a positive culture in up to 70% of patients, especially in children [9] . In general, infants are first colonized by 6 months of age and remain positive for approximately 4 months [10, 11] . Many factors influence the risk of developing disease and are more likely to promote the spread of pneumococcus than only episodic contact, such as contact time, repeated exposure, the quantity of transmitted bacteria, or crowded living conditions [12] . Host clearance mechanisms can be either mechanical, such as ciliary action, or immunological [6] . In the presence of coexisting infection (usually viral) or chronic ciliary damage (e.g. in smokers), these clearance mechanisms may be impaired and favour pneumococcal extension and replication.
Pneumococcal vaccines
The first pneumococcal vaccine trial started in 1911 with a killed whole-cell vaccine and was conducted among South African miners with a particularly high incidence of lobar pneumonia [13] . Thirty years later, a purified capsular polysaccharide vaccine was tested in military recruits in the USA [14] . Following encouraging results, two hexavalent polysaccharide vaccines became available in the USA in 1946. However, as the newly available antimicrobials had a 'miraculous' efficacy against lobar pneumonia, interest for these vaccines waned quickly, leading to their withdrawal from the market in 1954 [13, 15] . Pneumococcal vaccines became again a subject of interest in the 1970s because of the emergence of pneumococcal strains with a reduced susceptibility to antimicrobials.
Two different types of pneumococcal vaccines are currently available: a polysaccharide vaccine and conjugated vaccines ( Table 1) . The unconjugated pneumococcal polysaccharide vaccine (Pneumovax23 Ò , Merck, Whitehouse Station, NJ, USA) is non-adjuvanted and contains purified capsular polysaccharides from 23 different serotypes (Table 2) . Pneumococcal polysaccharide vaccine induces a B-cell response with the production of anticapsular opsonizing immunoglobulin, but no T-cell response. It is usually recommended for all adults over 65 years of age and for children older than 2 years with a high-risk medical condition, e.g. immunosuppression, asplenia (functional or anatomic), chronic diseases (including chronic heart, lung and liver diseases, diabetes mellitus, cerebrospinal fluid leaks and cochlear implant), alcohol abuse and tobacco use [16, 17] . Although the US Advisory Committee on Immunization Practices does not recommend routine re-vaccination with PPSV, some countries recommend a second dose after 5 years if the first dose was given before the age of 65 years, and in individuals <65 years old with certain high-risk conditions, such as immunosuppression and anatomical or functional asplenia [16] [17] [18] . Pneumococcal polysaccharide vaccine is usually not immunogenic in children <2 years old. To protect younger children, pneumococcal conjugated vaccines (PCV) were developed. Prevenar has replaced PCV7 and includes new serotypes in addition to the previous serotypes (Table 2 ). Recent studies showed that PCV13 is as immunogenic as PCV7 for both the common serotypes and additional serotypes [17, [19] [20] [21] . [17] . The safety profile is also comparable. Synflorix Ò (GlaxoSmithKline, London, UK) is a ten-valent PCV also used in Europe. Based on the ELISA threshold, non-inferiority of this PCV10 compared with PCV7 was demonstrated for eight out of ten serotypes (it was not reached for 6B and 23F), although post-hoc analysis of the percentage of children with opsonophagocytic titres ‡8 suggested noninferiority for the seven serotypes common to both vaccines [22] . Several studies have also shown that PCV10 could be co-administered with other childhood vaccines [23] [24] [25] [26] [27] , and that it could also induce immunological memory [28] . Since (Table 3 ) [29] . Simultaneous administration with other vaccines is possible, provided that the injection is administered with a separate syringe at a separate site [17] . National guidelines usually recommend two to three doses during the first year of life and a booster dose in the second year of life (Table 3) . Knuf et al. [30] demonstrated that the appropriate antibody response was achieved after the third dose of PCV7 in >98% (95% CI 95.84-100.66 for serotypes 9V and 23F; 95% CI 100-100 for the others) of subjects. Other authors confirmed these results and reported that the so-called 'protective' level (>0.35 mg/L) was reached in >82% of subjects after three doses, independent of the chosen immunization schedule (at 2, 4 and 6 months, or 2, 3 and 4 months) [31, 32] . WHO now recommends that approval of new pneumococcal vaccines should be based on non-inferiority data compared with PCV7, which should include the proof of development of protective and functional antibodies in vaccinated subjects after a primary series and a test of immune memory [33] . This was demonstrated for PCV13 where immunogenicity studies showed that it was not only similarly immunogenic against the PCV7-containing serotypes, but also against the new serotypes [17, 34, 35] . Any evaluation of the value of pneumococcal vaccination in children must take into account not only the immunogenicity data, but also the epidemiological and safety data.
Invasive pneumococcal disease
The overall estimated protection against IPD was reported in the pre-licensure study by Black et al. [36] in 2000 where 52 cases of IPD caused by vaccine serotypes (19F, 19F and 6B) were reported after immunizing > 38 000 young children in the intent-to-treat analysis [12] . The three vaccine failures included a fully vaccinated child, one child who developed acute myelogenous leukaemia after vaccination and became bacteraemic while receiving chemotherapy, and one child who had received a single dose of PCV7 almost a year earlier.
In the intention-to-treat analysis, the efficacy of PCV7 was shown to be 93.9% (95% CI 79.6-98.5, p 0.001) with a reduction in the total IPD burden of 89% (95% CI 73.7-95.85, p <0.001) following at least one dose [30] . Other laboratory-based and surveillance-based studies showed similar results, particularly in children <5 years old. In 1998-99, Whitney et al. [37] estimated the overall IPD rate in the USA at 24.3 cases per 100 000 and in 2001 at 17.3/100 000. This significant decrease was particularly important among children <2 years old, in whom the disease rate decreased by 69% (95% CI 62-75, p <0.001) [37] . Since then, these results have been confirmed in several studies [38] [39] [40] . The Active Bacterial Core surveillance, a core component of the US CDC Emerging Infections Programs network, showed a decrease of IPD of 76% (95% CI 73-79; 98.7 to 23.6/ 100 000 for all serotypes) in children <5 years old, and the serotypes included in PCV7 showed a decrease of 99.5% (95% CI 99-100; from 81.9 to 0.4/100 000) [41] . This was less spectacular in older children (5-17 years old), but remained significant (43% decrease, 95% CI 26-55 for all serotypes combined; form 5.17 to 4.2/100 000). Williams et al. [42] showed a decrease of 74% (p <0.001) in all children <2 years old in Australia. This reduction in the younger age group was less significant in Germany, where Rückinger et al. [43] reported a decrease of 45% of IPD (from 20, 95% CI 19.1-20.9 to 11, 95% CI 9.3-12.9/100 000 cases), which may be a result of the lower vaccination coverage (Table 3) .
Herd immunity
Interestingly, the vaccination of young children had an indirect effect on very young infants, i.e. those too young to be vaccinated. Givon-Lavi et al. [44] demonstrated this in Israel in a randomized double-blind study in which 262 children were followed for 2 years after receiving either PCV9 or a control vaccine. As expected, vaccine-serotype carriage decreased in PCV9 recipients, but a parallel reduction among their younger, unvaccinated siblings was also observed. Furthermore, when acquired, vaccine-serotype, drug-resistant S. pneumoniae was cleared faster in siblings of PCV9 PPSV23  1  2  3  4  5  6A  6B  7F  8  9N  9V  10A  11A  12F  14  15B  17F  18C  19A  19F  20  22F  23F  33F  PCV7  4  6B  9V  14  18C  19F  23F  PCV9  1  4  5  6B  9V  14  18C  19F  23F  PCV10  1  4  5  6B  7F  9V  14  18C  19F  23F  PCV11  1  3  4  5  6B  7F  9V  14  18C  19F  23F  PCV13  1  3  4  5  6A  6B  7F  9V  14  18C  19A  19F  23F  PCV15  1  3  4  5  6A  6B  7F  9V  14  18C  19A  19F  22F  23F  33F PPSV, pneumococcal polysaccharide vaccine; PCV, pneumococcal conjugate vaccine. The numbers following the vaccine reflect the valence. [45] . Similarly, while the hospitalization rate for IPD decreased in another study by 80% (95% CI 76-84) in the 0-1-year-old group (27.8-5.5/ 100 000 cases), the reduction was also significant in older children (65%, 95% CI 53-73, in 2-4 year olds; 53%, 95% CI 40-64, in 5-17 year olds), hence reflecting herd immunity [46] . Since the introduction of PCV, several studies have shown a decrease in the incidence of invasive pneumococcal disease not only in older children but also in adults, as well as a reduction of drug-resistant pneumococcal disease and carriage [41, [47] [48] [49] [50] [51] [52] . Haber et al. [53] calculated, using a quantitative model to estimate the herd effects on the incidence of invasive disease, that vaccinating young children with at least one dose significantly decreased invasive disease due to vaccine-serotypes in all age groups >5 years of age. O'Brien and Dagan [54] also summarized the early results regarding the impact of PCV on nasopharyngeal carriage of non-vaccine serotypes, which increased in several studies [55] .
Since the introduction of PCV7, serotypes not included in the vaccine have become much more prevalent. This phenomenon, known as serotype replacement, has probably occurred as the result of a combination of factors and is well summarized by Henriques-Normark et al. [56] . The most common new serotypes reported in IPD are 1, 19A, 3, 6A and 7F [57] . The greatest increase in children <5 years old was observed with 19A, but other serotypes such as 11, 15, 33 and 35 have also emerged in the last decade [38, 41, [58] [59] [60] [61] [62] . The emergence of 19A can be linked to several factors. It has been observed that countries with high rates of serotype 19A IPD or nasopharyngeal carriage also had high rates of antibiotic use, suggesting that antibiotic pressure played a role in the emergence of this serotype [63] [64] [65] [66] . In addition, authors have suggested that vaccine-induced serotype replacement, introduction of new clones, or secular trends explain the increase of serotype 19A. Reinert et al. [67] summarize the prevalence of serotype 19A in different settings. Although it became rapidly clear that serotype 19A would take the lead in industrialized countries as an important player in IPD, it was probably less expected that the proportion of antibiotic-resistant 19A would increase as fast in both PCV7-vaccinated and PCV7-non-vaccinated individuals [68] [69] [70] [71] [72] [73] . Manufacturers introduced PCV13 in 2010, a broader version of PCV7, which contained most of these emerging serotypes, and included serotypes-such as 1 and 5-which are more prevalent in developing countries as a cause of IPD-or such as serotypes 1 and 3 in pulmonary empyema [74, 75] . The results of the first surveillance data are only now being reported, but the observed and expected impact of PCV13 is clearly beneficial [76] [77] [78] [79] [80] [81] . In Alaskan Native children, a high-risk population, the incidence of IPD has decreased dramatically since the start of PCV13 vaccination and no new IPD cases were observed after these children received at least one dose of PCV13 [82] . Similarly, Active Bacterial Core surveillance data showed a decrease in IPD in vaccinated children <2 years old soon after implementation of PCV13 (in the fourth quarters of 2006-2008 compared with 2010: overall serotypes: 40.3-18.8/100 000 cases; PCV13 serotypes: 24.1-8.5/100 000 cases, both p <0.0001) [83] . 
Bacteraemia
Bacteraemia data are often included in the overall IPD results. However, a retrospective study of data from 1106 positive blood cultures in previously healthy children <3 years old in the USA showed a decrease in the proportion of pneumococcal bacteraemia from 78% in 1998-99 to 26% in 2001-02, with a decrease in the total number of positive blood cultures [84] . Similarly, in Spain, the total number of occult pneumococcal bacteraemia decreased by 57.5% (p <0.05) after the implementation of PCV7, and the rate attributed to PCV7 serotypes decreased significantly by 79% (p <0.01) [85] . In France, vaccine-type bacteraemia decreased by 64% from 14.8 to 5.3/100 000 children between 2001/02 and 2006, although PCV7 coverage in 6-12-month-old children was only 44% in 2006 [86] . According to epidemiological data, PCV13 should have an even more pronounced effect on bacteraemia [87, 88] .
Pneumonia
A reanalysis of all pneumonia cases of the PCV7 pre-licensure US study using the WHO standardized methodology for the classification of clinical pneumonia showed a per-protocol analysis effectiveness of 30.3% (95% CI 10.7-45.7; intent-to-treat analysis 25.5%; 95% CI 6.5-40.7) for the prevention of pneumonia [89] . In a randomized, double-blind, placebo-controlled trial with a nine-valent conjugate vaccine conducted in the Gambia in >17 000 children aged 6-51 weeks, the efficacy of PCV to prevent against a first episode of pneumonia was 37% (95% CI 27-45), with a 16% (95% CI 3-28) efficacy against mortality [90] . However, there was no significant efficacy in the severity of disease. Another US study of surveillance data found that non-bacteraemic pneumococcal pneumonia decreased by 47% in children <2 years old after PCV7 was introduced [46] . This was observed particularly in those <12 months old, in whom allcause pneumonia decreased from 1026.5 to 753.7/100 000 admissions in the post-PCV7 era. Of note, the effect of pneumococcal vaccination was not apparent for annual admission rates for pneumonia with empyema in young children [91] . This could be due to the fact that empyema is more frequent with certain serotypes that are not included in PCV7-such as 19A, 3 and 1-but that are now included in PCV13 [92] . This was confirmed by Spencer et al. [93] who recently reported a decrease in the incidence of empyema in children vaccinated with PCV13 (regression coefficient )0.26).
Meningitis
In a US surveillance study of children <5 years old, the reported decrease in vaccine-type serotypes was >95% (3.8-0.1/100 000 cases; 97%, p <0.001), representing a 64% decrease for all serotypes (4.7 to 1.7/100 000, p <0.001) [41] . In the Gambia, vaccine efficacy against meningitis was 92% (95% CI 44-100) for vaccine-type serotypes, but there was no significant change when considering all serotypes (vaccine efficacy 22%, 95% CI )84 to 68) [90] . In a US study of 1379 pneumococcal meningitis cases including 369 children (median age 15 months), the overall decrease between pre-PCV7 and post-PCV7 was less spectacular (30.1%, p <0.001) [94] . It was, however, higher for children <2 years old (64%, p <0.001, for all serotypes; 92.8%, p <0.001 for PCV7 serotypes; 83.5%, p 0.01 for PCV7-related serotypes), or when only PCV7 serotypes were considered (all ages combined, 73.3%, p <0.001) [94] . The authors describe also a significant increase (60.5%, p <0.001) in non-PCV7 serotypes, such as 19A, 22F and 35B. This is not reassuring because only 19A is included in PCV13. In France, a less significant decline (18%, p 0.03) was observed in children's pneumococcal meningitis rates after the introduction of PCV7, especially in children <2 years old (33%, 8.03-5.41/ 100 000 cases; p 0.0006), with a non-significant increase in older children (0.48-0.56/100 000 cases; p 0.3) [63, 95] . It is still unclear if this reflects a natural fluctuation in disease incidence or, for example, a serotype replacement.
Mucosal diseases
In the pre-licensure trial, PCV7 had 7% (95% CI 4.1-9.7) efficacy in preventing acute otitis media with an increased efficacy in children with recurrent episodes (9.3-22.8%) [36] . Furthermore, the incidence of ventilatory tube placement decreased by >20% (95% CI 1.5-35.2). In a Cochrane review the relative reduction of acute otitis media was between 6% (95% CI )4 to 16) and 7% (95% CI 4.1-9.7) in PCV7-vaccinated children <12 years, and the relative reduction of recurrent acute otitis media was between 9% (95% CI 3-15) and 56% (95% CI )2 to 81) [96] . In another study, PCV7 vaccination decreased pneumococcal acute otitis media by 48% (p <0.001), with a 38% (p <0.001) decrease in otorrhoea visits as a collateral benefit [97] . Although these reductions might appear marginal from an individual point of view, they may possibly have an important economic impact on public health because acute otitis media had an estimated total cost of US$440 million in 2004, all ages combined [96] [97] [98] .
Pneumococcal carriage
The ecological niche of S. pneumoniae is the nasopharynx [99] . Although not the main objective of pneumococcal vaccines, their efficacy in decreasing carriage has been disappointing. Some researchers found a decrease of the vaccine serotypes in colonization (p <0.05), but non-vaccine serotypes have been increasing and co-colonization with other microorganisms has remained stable [100] [101] [102] . However, it seems that the number of doses received has an impact on carriage: the more doses, the lower the colonization rate [100, 103] . Similarly, the impact on carriage appears to be serotype-dependent [104] . The less expected effect was the impact of the conjugate vaccination of children on adult carriage (83.9% decrease in PCV7-type pneumococcal carriage, p <0.001), which might explain the decrease in IPD in adults [52] . It is possible that pneumococcal vaccination selected in the nasopharynx serotypes that have less disease potential.
The impact of PCV13 on carriage remains unclear, but within 1 year of PCV13 implementation, Cohen et al. showed a significant decrease of serotypes 19A (p <0.001), 7F (p 0.01) and 6C (p 0.003) carriage among PCV13-vaccinated children without the emergence of new serotypes [65] . This led to the rapid replacement of PCV7 by PCV13 [105] [106] [107] . Nevertheless, some studies reported that antibody levels against certain serotypes (6B and 23F) did not achieve the protective threshold after a primary series of PCV13 vaccination [108] .
Side effects and safety profile
The safety profile of pneumococcal vaccines more than a decade after large-scale implementation is reassuring [19, 36] . Following pneumococcal vaccination, local reactions are mild in severity and usually last no more than 1 or 2 days. Systemic reactions, such as fever, irritability, decreased appetite, increased or decreased sleep, are also frequent (Table 4 ). In terms of serious side effects of PCV7, both the Vaccine Frequencies as defined by the European Medicines Agency: very common: >1/10 vaccine injections; common: >1/100 to <1/10 vaccine injections; uncommon: >1/1000 to <1/ 100 vaccine injections; rare: >1/10 000 to <1/1000 vaccine injections; very rare: £1/10 000 vaccine injections.
Adverse Event Reporting System and the European Medicines Agency report frequencies similar to other vaccines [17, 109] . These include anaphylactic and anaphylactoid reactions, serum sickness and thrombocytopenia. Post-licensure studies of PCV13 do not report an increased risk of serious adverse events compared with PCV7; nevertheless, surveillance is ongoing [19] [20] [21] 108, 110] . The concurrent administration of other routine childhood vaccinations does not increase the rate of side effects, nor does it reduce the elicited immune response [17] .
Challenges and future vaccines
The major challenges remaining with pneumococcal vaccination are PCV-serotype specificity, as well as its high manufacturing complexity and cost. As the regional distribution of predominant serotypes shifts, the coverage of currently used PCV may not be optimal worldwide. New strategies to improve vaccines are under investigation and development [111] , such as protein-based, serotype-independent, subunit vaccines, and whole-cell vaccines. Protein-based, serotype-independent vaccine targets proteins that are conserved in different (or most) pneumococcal serotypes. Candidate proteins include surface-expressed virulence factors to maximize the immune response. This approach would have the advantage of preventing the selection pressure and the emergence of new serotypes. The first protein studied was the pneumococcal surface protein A (PspA; currently in a phase I trial), but there are many other candidates, such as pneumolysin, pneumococcal histidine triad proteins, or pneumococcal surface adhesion A (PsaA). In the future, it is possible that reverse vaccinology may identify new proteins that are surface expressed, or that complete bacterial genome sequencing will pinpoint antigens conserved among clinical isolates [111] .
Killed whole-cell vaccine allows a large number of antigens to be present simultaneously. The possible advantages of this approach are low production costs, serotype-independent mechanisms of protection and, possibly, a variety of administration routes (intranasal, oral, sublingual, transcutaneous, subcutaneous and intramuscular). Phase I trials should have started at the end of 2011 with a vaccine administered parenterally [111] .
Although some of these vaccines are currently in phase I clinical trials, most are still in preclinical studies. In addition, the production of vaccines tailored according to regions, including only the locally prevalent serotypes, could become an option if production costs are controlled [112] . Novel technologies could make PCV more affordable worldwide and so expand coverage by reducing costs, especially in countries with limited resources [111] . The GAVI Alliance (formerly the 'Global Alliance for Vaccines and Immunisation'), has been instrumental in promoting the private-public partnership of all the main players in immunization into one decision-making body. Through this partnership, negotiations between industry and the creation of an Advanced Market Commitment for pneumococcal vaccine has already led to lower vaccine prices in several developing countries [113] .
In conclusion, more than a decade after the implementation of PCV in children, the impact on IPD especially is tremendous. In countries where it was implemented and coverage is high, reduction of IPD is significant and has impacts indirectly, through herd immunity, on non-vaccinated older and younger individuals. Pneumococcal disease remains an important global health issue, particularly in young children, and universal, affordable, available vaccination must be a priority.
